Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 504.34% and ...

The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated ...

Eli Lilly (LLY) closed at $796.03 in the latest trading session, marking a -0.44% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.82% for the day. Elsewhere, ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

A national medical firm has announced it will launch a $3 billion expansion of its Kenosha County facility and will bring 750 ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...